New study to settle debate: which drug works best for Kids' hair loss?

NCT ID NCT07381556

Recruiting now Disease control Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two common drugs, cyclosporine and methotrexate, to treat moderate-to-severe alopecia areata in children aged 2-17. The goal is to see which medicine helps regrow hair better over 9 months. Participants and their parents choose which treatment to try, and doctors track hair growth and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA (& OPHIASIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata alopecia totalis alopecia universalis alopecia universalis congenita

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA AREATA (& OPHIASIS) ALOPECIA AREATA(AA) ALOPECIA TOTALIS (AT) ALOPECIA TOTALIS/UNIVERSALIS ALOPECIA UNIVERSALIS (AU)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Erasmus MC
RECRUITING

Rotterdam, Netherlands

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.